DNA Vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers

Journal of Virology

Volumn 89, Issue 8, 2015, Pages 4158-4169

  Gupta, Sachin ^a   Clark, Emily S ^a   Termini, James M ^a   Boucher, Justin ^a   Kanagavelu, Saravana ^a,c   LeBranche, Celia C ^b   Abraham, Sakhi ^a   Montefiori, David C ^b   Khan, Wasif N ^a   Stone, Geoffrey W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; DNA VACCINE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; IMMUNOGLOBULIN G; INTERLEUKIN 12P70; NEUTRALIZING ANTIBODY; SURFACTANT PROTEIN D A PROLIFERATION INDUCING LIGAND; SURFACTANT PROTEIN D B CELL ACTIVATING FACTOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; B CELL ACTIVATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; TNFSF13 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANALYSIS OF VARIANCE; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENETICS; HIV INFECTIONS; IMMUNOLOGY; PLASMID; SERODIAGNOSIS;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, NEUTRALIZING; B-CELL ACTIVATING FACTOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PLASMIDS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; VACCINES, DNA;

EID: 84929636240     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02904-14     Document Type: Article

References (57)

1. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, Lamacchia M, Garratty E, Stiehm ER, Bryson YJ, Cao Y, Moore JP, Ho DD, Barbas CF. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027. http://dx.doi.org /10.1126/science.7973652.
2. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470. http://dx.doi.org/10.1038/nature10373.
3. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289. http://dx.doi.org/10.1126/science.1178746.
4. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861. http://dx.doi.org/10.1126/science.1187659.
5. Finton KA, Larimore K, Larman HB, Friend D, Correnti C, Rupert PB, Elledge SJ, Greenberg PD, Strong RK. 2013. Autoreactivity and exceptional CDR plasticity (but not unusual polyspecificity) hinder elicitation of the anti-HIV antibody 4E10. PLoS Pathog 9:e1003639. http://dx.doi .org/10.1371/journal.ppat.1003639.
6. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam SM. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-1908. http://dx.doi.org/10 .1126/science.1111781.
7. Verkoczy L, Diaz M, Holl TM, Ouyang YB, Bouton-Verville H, Alam SM, Liao HX, Kelsoe G, Haynes BF. 2010. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci U S A 107:181-186. http://dx .doi.org/10.1073/pnas.0912914107.
8. Zikherman J, Parameswaran R, Weiss A. 2012. Endogenous antigen tunes the responsiveness of naive B cells but not T cells. Nature 489:160-164. http://dx.doi.org/10.1038/nature11311.
9. McElrath MJ, Haynes BF. 2010. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33:542-554. http://dx.doi.org/10.1016/j.immuni.2010.09.011.
10. Pujanauski LM, Janoff EN, McCarter MD, Pelanda R, Torres RM. 2013. Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A 110:1422-1427. http://dx.doi.org/10.1073/pnas.1213713110.
11. Haynes BF, Moody MA, Liao HX, Verkoczy L, Tomaras GD. 2011. B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends Mol Med 17:108-116. http://dx.doi.org/10.1016/j .molmed.2010.10.008.
12. Pantophlet R. 2010. Antibody epitope exposure and neutralization of HIV-1. Curr Pharm Des 16:3729-3743. http://dx.doi.org/10.2174 /138161210794079182.
13. He B, Santamaria R, Xu W, Cols M, Chen K, Puga I, Shan M, Xiong H, Bussel JB, Chiu A, Puel A, Reichenbach J, Marodi L, Doffinger R, Vasconcelos J, Issekutz A, Krause J, Davies G, Li X, Grimbacher B, Plebani A, Meffre E, Picard C, Cunningham-Rundles C, Casanova JL, Cerutti A. 2010. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol 11:836-845. http://dx.doi.org/10.1038/ni.1914.
14. Khan WN. 2009. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol 183:3561-3567. http://dx.doi.org/10.4049 /jimmunol.0800933.
15. Puga I, Cols M, Barra CM, He B, Cassis L, Gentile M, Comerma L, Chorny A, Shan M, Xu W, Magri G, Knowles DM, Tam W, Chiu A, Bussel JB, Serrano S, Lorente JA, Bellosillo B, Lloreta J, Juanpere N, Alameda F, Baro T, de Heredia CD, Toran N, Catala A, Torrebadell M, Fortuny C, Cusi V, Carreras C, Diaz GA, Blander JM, Farber CM, Silvestri G, Cunningham-Rundles C, Calvillo M, Dufour C, Notarangelo LD, Lougaris V, Plebani A, Casanova JL, Ganal SC, Diefenbach A, Arostegui JI, Juan M, Yague J, Mahlaoui N, Donadieu J, Chen K, Cerutti A. 2012. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat Immunol 13:170-180. http://dx.doi.org/10.1038/ni.2194.
16. Treml LS, Carlesso G, Hoek KL, Stadanlick JE, Kambayashi T, Bram RJ, Cancro MP, Khan WN. 2007. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J Immunol 178:7531-7539. http://dx.doi.org/10.4049/jimmunol.178.12.7531.
17. Uslu K, Coleman AS, Allman WR, Katsenelson N, Bram RJ, Alugupalli KR, Akkoyunlu M. 2014. Impaired B cell receptor signaling is responsible for reduced TACI expression and function in X-linked immunodeficient mice. J Immunol 192:3582-3595. http://dx.doi.org/10.4049/jimmunol .1203468.
18. Lesley R, Xu Y, Kalled SL, Hess DM, Schwab SR, Shu HB, Cyster JG. 2004. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20:441-453. http://dx.doi.org /10.1016/S1074-7613(04)00079-2.
19. Liu Z, Davidson A. 2011. BAFF and selection of autoreactive B cells. Trends Immunol 32:388-394. http://dx.doi.org/10.1016/j.it.2011.06.004. 20. Ota M, Duong BH, Torkamani A, Doyle CM, Gavin AL, Ota T, Nemazee D. 2010. Regulation of the B cell receptor repertoire and selfreactivity by BAFF. J Immunol 185:4128-4136. http://dx.doi.org/10.4049 /jimmunol.1002176.
20. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, Brink R. 2004. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20:785-798. http://dx.doi.org/10.1016/j.immuni.2004 .05.010.
21. Bossen C, Cachero TG, Tardivel A, Ingold K, Willen L, Dobles M, Scott ML, Maquelin A, Belnoue E, Siegrist CA, Chevrier S, Acha-Orbea H, Leung H, Mackay F, Tschopp J, Schneider P. 2008. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 111:1004-1012. http://dx.doi.org/10.1182/blood-2007-09-110874.
22. Cerutti A, Puga I, Cols M. 2011. Innate control of B cell responses. Trends Immunol 32:202-211. http://dx.doi.org/10.1016/j.it.2011.02.004.
23. Mackay F, Schneider P. 2009. Cracking the BAFF code. Nat Rev Immunol 9:491-502. http://dx.doi.org/10.1038/nri2572.
24. Scholz JL, Oropallo MA, Sindhava V, Goenka R, Cancro MP. 2013. The role of Blymphocyte stimulator inBcell biology: implications for the treatment of lupus. Lupus 22:350-360. http://dx.doi.org/10.1177/0961203312469453.
25. Castigli E, Wilson SA, Scott S, Dedeoglu F, Xu S, Lam KP, Bram RJ, Jabara H, Geha RS. 2005. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 201:35-39. http://dx.doi.org/10.1084/jem.20032000.
26. Rickert RC, Jellusova J, Miletic AV. 2011. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev 244:115-133. http://dx.doi.org/10.1111/j.1600-065X.2011.01067.x.
27. Groom JR, Fletcher CA, Walters SN, Grey ST, Watt SV, Sweet MJ, Smyth MJ, Mackay CR, Mackay F. 2007. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 204:1959-1971. http://dx.doi.org/10.1084/jem.20062567.
28. Tertilt C, Joh J, Krause A, Chou P, Schneeweiss K, Crystal RG, Worgall S. 2009. Expression of B-cell activating factor enhances protective immunity of a vaccine against Pseudomonas aeruginosa. Infect Immun 77:3044-3055. http://dx.doi.org/10.1128/IAI.00927-08.
29. O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, Lin LL, Mantchev GT, Bram RJ, Noelle RJ. 2004. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199: 91-98. http://dx.doi.org/10.1084/jem.20031330.
30. Benson MJ, Dillon SR, Castigli E, Geha RS, Xu S, Lam KP, Noelle RJ. 2008. The dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 180:3655-3659. http://dx.doi.org /10.4049/jimmunol.180.6.3655.
31. Ou X, Xu S, Lam KP. 2012. Deficiency in TNFRSF13B (TACI) expands T-follicular helper and germinal center B cells via increased ICOS-ligand expression but impairs plasma cell survival. Proc Natl Acad Sci U S A 109:15401-15406. http://dx.doi.org/10.1073/pnas.1200386109.
32. Melchers M, Bontjer I, Tong T, Chung NP, Klasse PJ, Eggink D, Montefiori DC, Gentile M, Cerutti A, Olson WC, Berkhout B, Binley JM, Moore JP, Sanders RW. 2012. Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol 86:2488-2500. http://dx.doi.org/10.1128/JVI.06259-11.
33. Kanagavelu SK, Snarsky V, Termini JM, Gupta S, Barzee S, Wright JA, Khan WN, Kornbluth RS, Stone GW. 2012. Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine. Vaccine 30:691-702. http://dx.doi.org/10.1016/j.vaccine .2011.11.088.
34. Stone GW, Barzee S, Snarsky V, Kee K, Spina CA, Yu XF, Kornbluth RS. 2006. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol 80:1762-1772. http://dx.doi.org/10.1128/JVI.80.4.1762-1772.2006.
35. Stone GW, Barzee S, Snarsky V, Spina CA, Lifson JD, Pillai VK, Amara RR, Villinger F, Kornbluth RS. 2006. Macaque multimeric soluble CD40 ligand and GITR ligand constructs are immunostimulatory molecules in vitro. Clin Vaccine Immunol 13:1223-1230. http://dx.doi.org/10.1128 /CVI.00198-06.
36. Qiu JT, Liu B, Tian C, Pavlakis GN, Yu XF. 2000. Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 Gag by using DNA expression vectors that target Gag antigen to the secretory pathway. J Virol 74:5997-6005. http://dx.doi .org/10.1128/JVI.74.13.5997-6005.2000.
37. Stone GW, Barzee S, Snarsky V, Santucci C, Tran B, Kornbluth RS. 2009. Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA. J Thorac Oncol 4:802-808. http://dx.doi.org/10.1097/JTO.0b013e3181a8634d.
38. Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A. 2003. ExPASy: The proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res 31:3784-3788. http://dx.doi.org/10.1093/nar /gkg563.
39. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbert PB, Self SG, Korber BT, Montefiori DC, Mascola JR. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84: 1439-1452. http://dx.doi.org/10.1128/JVI.02108-09.
40. Ross TM, Xu Y, Green TD, Montefiori DC, Robinson HL. 2001. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNAvaccination with gp120-C3d fusion proteins. AIDS ResHumRetroviruses 17:829-835. http://dx.doi.org/10.1089/088922201750252025.
41. Lieschke GJ, Rao PK, Gately MK, Mulligan RC. 1997. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo. Nat Biotechnol 15:35-40. http://dx.doi.org/10.1038/nbt0197-35.
42. Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, Lu S. 2008. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 82:7369-7378. http://dx.doi.org/10.1128/JVI.00562-08.
43. Wang S, Arthos J, Lawrence JM, Van Ryk D, Mboudjeka I, Shen S, Chou TH, Montefiori DC, Lu S. 2005. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol 79:7933-7937. http://dx.doi.org/10.1128 /JVI.79.12.7933-7937.2005.
44. Rahman ZS, Manser T. 2004. B cells expressing Bcl-2 and a signalingimpaired BAFF-specific receptor fail to mature and are deficient in the formation of lymphoid follicles and germinal centers. J Immunol 173: 6179-6188. http://dx.doi.org/10.4049/jimmunol.173.10.6179.
45. Rahman ZS, Rao SP, Kalled SL, Manser T. 2003. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med 198:1157-1169. http://dx.doi.org/10 .1084/jem.20030495.
46. Yoon SO, Zhang X, Berner P, Blom B, Choi YS. 2009. Notch ligands expressed by follicular dendritic cells protect germinal center B cells from apoptosis. J Immunol 183:352-358. http://dx.doi.org/10.4049/jimmunol .0803183.
47. Holl TM, Yang G, Kuraoka M, Verkoczy L, Alam SM, Moody MA, Haynes BF, Kelsoe G. 2014. Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes. J Immunol 192:3269-3279. http://dx.doi.org/10 .4049/jimmunol.1302829.
48. Liu M, Yang G, Wiehe K, Nicely NI, Vandergrift NA, Rountree W, Bonsignori M, Alam SM, Gao J, Haynes BF, Kelsoe G. 2015. Polyreactivity and autoreactivity among HIV-1 antibodies. J Virol 89:784-798. http://dx.doi.org/10.1128/JVI.02378-14.
49. Verkoczy L, Kelsoe G, Haynes BF. 2014. HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. PLoS Pathog 10:e1004073. http://dx.doi.org/10.1371/journal.ppat.1004073.
50. Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt-Supprian M. 2004. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol 173: 2245-2252. http://dx.doi.org/10.4049/jimmunol.173.4.2245.
51. Wolf AI, Mozdzanowska K, Quinn WJ, III, Metzgar M, Williams KL, Caton AJ, Meffre E, Bram RJ, Erickson LD, Allman D, Cancro MP, Erikson J. 2011. Protective antiviral antibody responses in a mouse model of influenza virus infection require TACI. J Clin Invest 121:3954-3964. http://dx.doi.org/10.1172/JCI57362.
52. Ishizaka ST, Piacente P, Silva J, Mishkin EM. 1995. IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoprotein D monoclonal antibodies. J Infect Dis 172:1108-1111. http://dx.doi.org/10.1093/infdis/172.4.1108.
53. Morello CS, Kraynyak KA, Levinson MS, Chen Z, Lee KF, Spector DH. 2012. Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge. Vaccine 30:6541-6550. http://dx.doi.org/10 .1016/j.vaccine.2012.08.049.
54. Sin JI, Bagarazzi M, Pachuk C, Weiner DB. 1999. DNA priming-protein boosting enhances both antigen-specific antibody and Th1-type cellular immune responses in a murine herpes simplex virus-2 gD vaccine model. DNA Cell Biol 18:771-779. http://dx.doi.org/10.1089/104454999314917.
55. Bonsignori M, Wiehe K, Grimm SK, Lynch R, Yang G, Kozink DM, Perrin F, Cooper AJ, Hwang KK, Chen X, Liu M, McKee K, Parks RJ, Eudailey J, Wang M, Clowse M, Criscione-Schreiber LG, Moody MA, Ackerman ME, Boyd SD, Gao F, Kelsoe G, Verkoczy L, Tomaras GD, Liao HX, Kepler TB, Montefiori DC, Mascola JR, Haynes BF. 2014. An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. J Clin Invest 124:1835-1843. http://dx.doi.org/10.1172/JCI73441.
56. Haynes BF, Verkoczy L. 2014. AIDS/HIV. Host controls of HIV neutralizing antibodies. Science 344:588-589. http://dx.doi.org/10.1126/science .1254990.
57. Verkoczy L, Chen Y, Zhang J, Bouton-Verville H, Newman A, Lockwood B, Scearce RM, Montefiori DC, Dennison SM, Xia SM, Hwang KK, Liao HX, Alam SM, Haynes BF. 2013. Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses. J Immunol 191:2538-2550. http://dx.doi.org/10.4049/jimmunol .1300971.